Matthias Cheung, PhD, Discusses Current Federal Legislation and Ongoing Policies Regarding Orphan Drugs and Rare Disease

Although allogenic stem cell transplant is increasingly used to treat multiple myeloma (MM) and other hematological conditions, there have been mixed efficacy results in the context of MM.

On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.

The analysis, which was presented during the 64th ASH Annual Meeting and Exposition, highlighted stringent complete response data for patients 65 years and older and those with high cytogenic risk.

On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.

Researchers explored the case of a 40-year-old woman with polycythemia vera (PV) who developed a portal vein occlusion 1.5 months postpartum after C-section.

Results presented during the 64th American Society of Hematology Annual Meeting and Exposition could offer an effective option for those with relapsed or refractory DLBCL, even as chimeric antigen receptor T-cell therapy becomes standard of care for many patients.